Advertisement

Topics

Ipsen And Its Partner Exelixis Announce Independent Radiology Committee Review Confirms Results From Phase II CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma

20:00 EDT 19 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Ipsen And Its Partner Exelixis Announce Independent Radiology Committee Review Confirms Results From Phase II CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma

NEXT ARTICLE

More From BioPortfolio on "Ipsen And Its Partner Exelixis Announce Independent Radiology Committee Review Confirms Results From Phase II CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma"

Advertisement
Quick Search
Advertisement
Advertisement